Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

TENAYA and LUCERNE Investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)729-740
Number of pages12
JournalThe Lancet
Volume399
Issue number10326
DOIs
StatePublished - Feb 19 2022

ASJC Scopus Subject Areas

  • General Medicine

Cite this